Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E108.40 EPS (ttm)1.60 Insider Own0.20% Shs Outstand256.26M Perf Week-1.31%
Market Cap44.33B Forward P/E36.96 EPS next Y4.68 Insider Trans-48.14% Shs Float254.44M Perf Month-5.25%
Income415.10M PEG1.88 EPS next Q1.01 Inst Own98.10% Short Float0.96% Perf Quarter10.78%
Sales2.62B P/S16.90 EPS this Y327.00% Inst Trans1.18% Short Ratio1.59 Perf Half Y10.01%
Book/sh10.57 P/B16.37 EPS next Y24.33% ROA11.00% Target Price196.52 Perf Year13.28%
Cash/sh10.80 P/C16.02 EPS next 5Y57.70% ROE18.60% 52W Range136.50 - 183.39 Perf YTD15.44%
Dividend- P/FCF62.35 EPS past 5Y47.60% ROI8.80% 52W High-4.63% Beta1.47
Dividend %- Quick Ratio3.60 Sales past 5Y10.30% Gross Margin87.30% 52W Low28.13% ATR3.43
Employees2300 Current Ratio3.70 Sales Q/Q-40.20% Oper. Margin3.90% RSI (14)53.73 Volatility1.43% 2.12%
OptionableYes Debt/Eq0.22 EPS Q/Q-24.20% Profit Margin15.80% Rel Volume0.31 Prev Close173.00
ShortableYes LT Debt/Eq0.22 EarningsJul 25 AMC Payout0.00% Avg Volume1.53M Price174.90
Recom1.80 SMA20-0.49% SMA504.38% SMA20010.06% Volume339,642 Change1.10%
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Mar-31-17Upgrade Maxim Group Hold → Buy $143
Mar-17-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Mar-09-17Initiated UBS Buy $106
Mar-01-17Initiated Citigroup Buy $105
Aug-16-18 10:04AM  Vertex Awards Two College Students Full Scholarships to the University of Massachusetts Business Wire
09:07AM  Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children Zacks
Aug-15-18 04:39PM  Vertex cystic fibrosis drug gets expanded approval for use in infants Reuters
03:29PM  FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene Business Wire
08:48AM  The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue Benzinga
Aug-14-18 10:55AM  Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit Zacks
Aug-13-18 01:26PM  The Week Ahead: Nvidia, Retailer Earnings In Focus Benzinga
10:04AM  7 Fast-Growing Stocks to Buy Today InvestorPlace
Aug-10-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Immunomedics, Vertex Pharmaceuticals, Ralph Lauren, Alliant Energy, TreeHouse Foods, and Lincoln National New Research Emphasizes Economic Growth GlobeNewswire
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
10:00AM  Is Crispr Therapeutics Stock Grossly Overvalued? Motley Fool
09:27AM  Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2 Zacks
09:17AM  Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise Zacks
Aug-08-18 04:18PM  3 Top Biotech Stocks to Buy in August Motley Fool
10:49AM  Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2 Zacks
07:52AM  Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges Zacks
Aug-07-18 03:48PM  FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease Business Wire
03:32PM  8 Biotechs Still Worth Buying After a Sector Surge Barrons.com
Aug-06-18 04:00PM  This stock sector most often beats analysts estimates MarketWatch
03:30PM  The Week Ahead: Earnings From Disney, Roku And Snap, Rite Aid Votes On Albertsons Deal Benzinga
Aug-03-18 03:09PM  Why Boston and central Texas have so many of the best-paying companies in the U.S. Here's where other cities are missing out. American City Business Journals
Aug-02-18 10:35AM  Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track Zacks
08:00AM  Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study Reuters
Aug-01-18 09:34AM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit Zacks
Jul-31-18 07:39AM  9 Near-Monopolies That Are Legal in America Motley Fool
Jul-30-18 11:24PM  Edited Transcript of VRTX earnings conference call or presentation 25-Jul-18 8:30pm GMT Thomson Reuters StreetEvents
01:47PM  Here's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than Revenue Motley Fool
12:09PM  Could Gilead Merge With Pfizer Or Vertex To Solve Its CEO Problem? Investor's Business Daily
Jul-27-18 10:22AM  Vertex Receives European CHMP Positive Opinion for SYMKEVI® (tezacaftor/ivacaftor) for People with Cystic Fibrosis Aged 12 and Older with Certain Mutations in the CFTR Gene Business Wire
10:19AM  3 Reasons Why Vertex Pharmaceuticals Stock Isn't Nearly as Expensive as It Looks Motley Fool
Jul-26-18 02:42PM  Vertex and Alexion Are Schooling Big Biotech Bloomberg
02:34PM  Vertex Pharmaceuticals (VRTX) Q2 2018 Earnings Conference Call Transcript Motley Fool
01:40PM  Vertex says sales of cystic fibrosis drugs could hit $3B this year American City Business Journals
01:23PM  MARKETS: Facebook aside, earnings are rolling in positive and boosting stocks Yahoo Finance Video
11:51AM  Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates Zacks
Jul-25-18 04:10PM  Vertex: 2Q Earnings Snapshot Associated Press
04:01PM  Vertex Reports Second-Quarter 2018 Financial Results Business Wire
02:30PM  Vertex Pharmaceuticals Incorporated to Host Earnings Call ACCESSWIRE
01:10PM  3 'Strong Buy' Healthcare Stocks Poised to Surge TheStreet.com
08:27AM  Earnings Preview For Vertex Pharmaceuticals Benzinga
07:45AM  Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks ACCESSWIRE
Jul-24-18 03:24PM  4 of the Best U.S. Stocks to Buy Today for Long-Term Growth InvestorPlace
08:37AM  Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK Zacks
Jul-23-18 11:06AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jul-20-18 06:00AM  7 High Return Stocks for Your Portfolio Investopedia
Jul-16-18 01:05PM  CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech Motley Fool
Jul-12-18 04:01PM  Vertex to Announce Second Quarter 2018 Financial Results on July 25 Business Wire
Jul-08-18 03:15PM  Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far Motley Fool
Jul-05-18 02:40PM  Drug pricing debate could heat up in July CNBC Videos
Jul-02-18 10:06AM  Company News For Jul 2, 2018 Zacks
09:02AM  Vertex's Shares Rally as a Rival's CF Candidate Disappoints Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Acceleron Pharma and Vertex Pharmaceuticals ACCESSWIRE
Jun-29-18 06:07PM  After the Bell: For the Dow, a Good Quarter, but a Bad Year Barrons.com +15.16%
04:52PM  Vertex Pops As Rival Disappoints In Cystic Fibrosis And AbbVie Opts Out Investor's Business Daily
03:27PM  Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results TheStreet.com
12:19PM  Why Vertex Pharmaceuticals Incorporated Stock Surged 14% Today Motley Fool
10:45AM  Bad News Delivers a Decisive Blow to Galapagos N.V. Motley Fool
09:41AM  Stocks Jump As Nike, Wells Fargo, Vertex Lead Early Rally Investor's Business Daily
08:11AM  Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos Benzinga
04:53AM  Premarket: Futures Rise As Banks Rally On Stress Test; Nike Spikes Investor's Business Daily
Jun-28-18 11:19AM  Health Canada Approves PrSYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene Business Wire
Jun-26-18 11:26AM  The 10 Fastest-Growing Stocks to Invest In Right Now InvestorPlace
06:30AM  This Biotech Has the Most Valuable Pipeline Asset in the World -- Is the Stock a Buy? Motley Fool
Jun-25-18 09:31AM  You Should Consider Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Because Of These Reasons Simply Wall St.
Jun-21-18 03:25PM  Vertexs Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis Business Wire
11:49AM  3 Big Biotechs That Can Beat the Market Investopedia
Jun-20-18 11:30AM  2 High-Flying Biotech Stocks With Even More Room to Grow Motley Fool
Jun-18-18 01:00PM  Vertex Opens Expanded Research Site in San Diego Business Wire
07:00AM  Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor) Business Wire
Jun-15-18 10:37AM  Big Biotech Set for Earnings Blowout? Barrons.com
Jun-14-18 09:30AM  The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program Business Wire
Jun-12-18 05:00AM  The Quant King, the Drug Hunter, and the Quest to Unlock New Cures Bloomberg
Jun-11-18 10:31AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
Jun-08-18 09:18AM  Now's the Time to Buy These 3 Stocks Motley Fool
Jun-07-18 05:20PM  Vertex Gets Some Breathing Room As Rival Disappoints In Cystic Fibrosis Investor's Business Daily
04:30AM  Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF Business Wire
Jun-06-18 04:01PM  Vertex to Present at the Goldman Sachs Healthcare Conference on June 13 Business Wire
08:31AM  Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO Zacks
Jun-05-18 04:10PM  Interested In Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? Heres What Its Recent Performance Looks Like Simply Wall St.
07:20AM  Free Technical Research on Versartis and Three More Biotech Equities ACCESSWIRE
06:33AM  Buy These 2 Biotech Stocks on the Dip After an FDA Delay Motley Fool
12:21AM  After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall InvestorPlace
Jun-01-18 08:41AM  Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex Zacks
May-31-18 03:10PM  Should You Buy the Dip in CRISPR Therapeutics? Zacks
11:45AM  3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickle Cell Candidate Benzinga
11:05AM  Peaking late: How Vertex became biotech's model citizen American City Business Journals
10:09AM  Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA Zacks
08:31AM  4 Reasons Not to Worry About Crispr Therapeutics AG's Latest Setback Motley Fool
07:55AM  Is Crispr Therapeutics Stock a Bad News Buy? Motley Fool
07:02AM  Dow Jones Futures: Hot Biotech Dives On FDA; 3 Breakout Bids With Flaws Investor's Business Daily
May-30-18 08:19PM  CRISPR, Vertex say FDA puts brakes on upcoming gene editing trial American City Business Journals
05:02PM  Crispr, Vertex shares fall after FDA halts sickle-cell disease trial MarketWatch
04:51PM  FDA places clinical hold on drug CNBC Videos
04:46PM  Gene-Therapy Company Crispr Drops as FDA Puts Trial on Hold Bloomberg
04:30PM  CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
May-28-18 02:50AM  Vertex Pharmaceuticals (VRTX) Down 1.2% Since Earnings Report: Can It Rebound? Zacks
May-25-18 08:10PM  3 Stocks That Could Put Alibaba's Returns to Shame Motley Fool
May-16-18 10:09AM  The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex Zacks
07:00AM  CRISPR Stocks Deserve a Second Look. Here's Why. Investopedia
May-10-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery Communications, Vertex Pharmaceuticals, The New York Times, Palatin Technologies, and E*TRADE Financial New Research Emphasizes Economic Growth GlobeNewswire
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise103.095,803598,21152,555Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Option Exercise86.5280969,99516,896Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Option Exercise86.522,330201,59241,443Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Option Exercise86.521,942168,02248,604Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59241,939Aug 07 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale174.205,8031,010,88346,752Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Sale174.20809140,92816,087Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Sale174.202,330405,88639,113Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Sale175.101,942340,05046,662Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Sale174.202,330405,88639,609Aug 07 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise111.334,280476,47948,907Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,376Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Option Exercise91.051,796163,52640,909Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Option Exercise91.052,155196,21348,817Aug 06 06:19 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale176.784,280756,61646,752Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Sale174.591,289225,04716,087Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Sale174.591,796313,56439,113Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Sale176.732,155380,85246,662Aug 06 06:19 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Option Exercise96.872,125205,84948,877Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Option Exercise96.871,719166,52048,381Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Option Exercise131.8923,3753,082,92962,488Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Option Exercise96.8786083,30816,947Jul 18 05:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Sale179.852,125382,18146,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Sale180.361,719310,04246,662Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Sale182.0023,3754,254,25039,113Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Sale179.85860154,67116,087Jul 18 05:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Option Exercise131.896,375840,79953,127Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Option Exercise96.8712,0311,165,44358,693Jul 17 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Sale179.006,3751,141,12546,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Sale180.0012,0312,165,58046,662Jul 17 06:30 PM
Silva Paul MSVP & Corp ControllerJul 12Option Exercise90.2986077,64916,947Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Option Exercise90.292,125191,86641,734Jul 16 04:37 PM
Silva Paul MSVP & Corp ControllerJul 12Sale175.02860150,51716,087Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Sale175.022,125371,91839,609Jul 16 04:37 PM
Parini MichaelEVP, CL&AOJul 05Option Exercise122.454,250520,41343,859Jul 09 06:14 PM
Parini MichaelEVP, CL&AOJul 05Sale168.384,250715,61539,609Jul 09 06:14 PM
Sachdev AmitEVP, CROJun 29Option Exercise88.904,096364,14850,758Jul 03 04:12 PM
Silva Paul MSVP & Corp ControllerJun 29Option Exercise91.502,957270,56917,376Jul 03 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Option Exercise89.153,708330,57850,460Jul 03 04:20 PM
SMITH IAN FEVP, COOJun 29Option Exercise131.8923,3753,082,92970,074Jul 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Option Exercise87.1313,4451,171,39783,444Jul 03 04:29 PM
Sachdev AmitEVP, CROJun 29Sale167.634,096686,61546,662Jul 03 04:12 PM
Silva Paul MSVP & Corp ControllerJun 29Sale166.522,957492,38516,087Jul 03 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Sale169.003,708626,65246,752Jul 03 04:20 PM
SMITH IAN FEVP, COOJun 29Sale166.3023,3753,887,17346,699Jul 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Sale164.9844,3317,313,59639,113Jul 03 04:29 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Option Exercise83.36106,5008,877,840297,260Jun 26 05:18 PM
SMITH IAN FEVP, COOJun 22Option Exercise109.144,250463,84550,949Jun 26 05:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Option Exercise109.144,250463,84551,002Jun 26 05:20 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Sale160.00140,21122,433,760157,049Jun 26 05:18 PM
SMITH IAN FEVP, COOJun 22Sale160.004,250680,00046,699Jun 26 05:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Sale159.004,250675,75046,752Jun 26 05:20 PM
Bhatia Sangeeta N.DirectorJun 04Sale152.05875133,0444,879Jun 05 05:39 PM
ALTSHULER DAVIDEVP, Global Research and CSOMay 15Sale155.789815,26669,999May 16 04:48 PM
Sachdev AmitEVP, CROMay 15Sale155.788312,93046,662May 16 05:06 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale155.7813821,49846,752May 16 05:11 PM
SMITH IAN FEVP, COOMay 15Sale155.7821733,80446,699May 16 05:21 PM
Parini MichaelEVP, CL&AOMay 15Sale155.788513,24139,609May 16 05:24 PM
Silva Paul MSVP & Corp ControllerMay 15Sale155.7820131,31216,087May 16 05:27 PM
Parini MichaelEVP, CL&AOMay 03Option Exercise86.522,330201,59241,939May 04 04:23 PM
Parini MichaelEVP, CL&AOMay 03Sale149.502,330348,33539,609May 04 04:23 PM
SMITH IAN FEVP, COOApr 26Option Exercise108.6553,1255,771,98999,824Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 26Option Exercise122.4538,2504,683,71377,859Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 26Sale160.1253,1258,506,37546,699Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 26Sale159.5638,2506,103,17039,609Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 25Option Exercise84.4514,1721,196,78678,667Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 25Option Exercise90.292,125191,86642,123Apr 27 04:38 PM
SMITH IAN FEVP, COOApr 25Sale155.3331,9684,965,52646,699Apr 27 04:37 PM
Parini MichaelEVP, CL&AOApr 25Sale155.222,514390,23339,609Apr 27 04:38 PM
Silva Paul MSVP & Corp ControllerApr 18Option Exercise90.2985977,55916,946Apr 19 05:37 PM
Silva Paul MSVP & Corp ControllerApr 18Sale166.05859142,63716,087Apr 19 05:37 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 16Option Exercise96.872,125205,84948,877Apr 18 02:50 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 16Sale163.012,125346,39646,752Apr 18 02:50 PM
Silva Paul MSVP & Corp ControllerApr 02Sale161.213,438554,24916,087Apr 04 05:07 PM
Sachdev AmitEVP, CROMar 09Option Exercise96.8713,7501,331,96360,412Mar 12 05:36 PM
Sachdev AmitEVP, CROMar 09Sale175.0013,7502,406,25046,662Mar 12 05:36 PM
MCGLYNN MARGARET GDirectorMar 02Option Exercise81.5410,000815,40016,312Mar 05 06:13 PM
MCGLYNN MARGARET GDirectorMar 02Sale170.0010,0001,700,0006,312Mar 05 06:13 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 26Option Exercise86.521,554134,45253,211Feb 28 09:22 AM
Sachdev AmitEVP, CROFeb 26Option Exercise91.052,155196,21348,817Feb 28 09:30 AM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 26Sale169.006,4591,091,57146,752Feb 28 09:22 AM
Sachdev AmitEVP, CROFeb 26Sale170.002,155366,35046,662Feb 28 09:30 AM
Silva Paul MSVP & Corp ControllerFeb 20Sale158.493,437544,73019,525Feb 21 06:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 13Sale151.834,044614,00151,657Feb 15 04:23 PM
Sachdev AmitEVP, CROFeb 12Sale150.8417,7962,684,41146,662Feb 14 06:23 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 12Sale150.825,122772,49369,663Feb 14 06:15 PM
LEIDEN JEFFREY MCEO & PresidentFeb 12Sale150.8323,9053,605,547190,658Feb 14 06:06 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 12Sale150.826,403965,67169,999Feb 14 05:53 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 12Sale152.826,8241,042,83355,701Feb 14 06:16 PM
Parini MichaelEVP, CL&AOFeb 05Option Exercise86.522,330201,59227,823Feb 07 05:56 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 05Option Exercise109.143,594392,24956,118Feb 07 06:16 PM
Sachdev AmitEVP, CROFeb 05Option Exercise81.274,520367,32743,683Feb 07 06:26 PM
Silva Paul MSVP & Corp ControllerFeb 05Option Exercise80.862,098169,64718,732Feb 07 05:37 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 05Option Exercise93.238,500792,41350,452Feb 07 05:46 PM
Silva Paul MSVP & Corp ControllerFeb 05Sale163.082,098342,14216,634Feb 07 05:37 PM
Sachdev AmitEVP, CROFeb 05Sale163.014,520736,80039,163Feb 07 06:26 PM
Chodakewitz JeffreyEVP GMDA, CMOFeb 05Sale161.463,594580,30452,524Feb 07 06:16 PM
Parini MichaelEVP, CL&AOFeb 05Sale163.082,330379,97625,493Feb 07 05:56 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 05Sale163.088,5001,386,18041,952Feb 07 05:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 02Option Exercise91.052,156196,30444,108Feb 05 05:11 PM